ANTX RSI Chart
Last 7 days
-81.8%
Last 30 days
-82.6%
Last 90 days
-77.5%
Trailing 12 Months
-74.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 94.0K | 307.0K | 748.0K | 1.4M |
2021 | 0 | 0 | 0 | 69.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 18, 2024 | zakrzewski joseph s | sold | -1,911,410 | 19.1141 | -100,000 | - |
Jan 16, 2024 | aziz kabeer | sold | -312,573 | 19.65 | -15,907 | - |
Jan 16, 2024 | aziz kabeer | sold | -1,652,430 | 19.65 | -84,093 | - |
Jan 16, 2024 | adjuvant global health technology fund, l.p. | sold | -1,652,430 | 19.65 | -84,093 | - |
Jan 16, 2024 | adjuvant global health technology fund, l.p. | sold | -312,573 | 19.65 | -15,907 | - |
Jan 12, 2024 | readnour robin shane | sold | -31,228 | 21.915 | -1,425 | - |
Jan 10, 2024 | readnour robin shane | sold | -80,443 | 21.9251 | -3,669 | - |
Jan 09, 2024 | krause kevin michael | sold | -149,367 | 20.1385 | -7,417 | chief strategy officer |
Jan 09, 2024 | krause kevin michael | acquired | 34,015 | 4.5861 | 7,417 | chief strategy officer |
Jan 02, 2024 | krause kevin michael | acquired | 1,084 | 0.42 | 2,583 | chief strategy officer |
Which funds bought or sold ANTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 11.99 | 6,454,140 | 21,567,600 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | new | - | 575,606 | 575,606 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | new | - | 3,840,000 | 3,840,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 1,218,030 | 1,218,030 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 1,295 | 856,000 | 907,000 | -% |
Feb 15, 2024 | Nantahala Capital Management, LLC | added | 39.17 | 4,437,260 | 10,174,400 | 0.30% |
Feb 14, 2024 | 683 Capital Management, LLC | new | - | 274,402 | 274,402 | 0.02% |
Feb 14, 2024 | ACUTA CAPITAL PARTNERS, LLC | added | 892 | 2,490,820 | 2,704,680 | 1.52% |
Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 394,392 | 394,392 | -% |
Feb 14, 2024 | TCG Crossover Management, LLC | unchanged | - | 11,810,900 | 54,876,500 | 6.09% |
Unveiling AN2 Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to AN2 Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.42 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.8B | 1.8B | -42.7 | 10.28 | ||||
BMRN | 15.8B | 2.4B | 94.39 | 6.54 | ||||
INCY | 13.1B | 3.7B | 21.93 | 3.55 | ||||
MID-CAP | ||||||||
APLS | 6.8B | 396.6M | -12.94 | 17.25 | ||||
BBIO | 4.8B | - | -7.42 | 60.35 | ||||
AXSM | 3.6B | 270.6M | -14.96 | 13.22 | ||||
ARWR | 3.5B | 240.7M | -11.8 | 14.55 | ||||
ACAD | 3.0B | 726.4M | -49.68 | 4.19 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.52 | 4.76 | ||||
NVAX | 740.4M | 983.7M | -1.36 | 0.75 | ||||
CRBP | 458.3M | 881.7K | -10.28 | 530.54 | ||||
INO | 250.8M | 4.9M | -1.86 | 51.53 | ||||
IBIO | 3.7M | 2.1M | -0.13 | 2.14 |
AN2 Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | 35.2% | 630 | 466 | 228 | 27.00 | 27.00 | 25.00 | 15.00 | 2.00 |
Operating Expenses | 6.0% | 12,476 | 11,770 | 10,333 | 7,683 | 7,594 | 6,932 | 4,998 | 2,050 |
S&GA Expenses | 11.4% | 3,724 | 3,342 | 3,635 | 2,050 | 1,782 | 1,587 | 898 | 401 |
R&D Expenses | 17.8% | 8,752 | 7,428 | 6,698 | 5,633 | 5,312 | 5,345 | 3,850 | 1,649 |
Net Income | -4.4% | -11,842 | -11,339 | -10,120 | -7,655 | -7,545 | -6,943 | -5,007 | -2,048 |
Net Income Margin | 38.1% | -30.32* | -49.01* | -105.09* | -288.83* | -312.22* | - | - | - |
Free Cashflow | 19.5% | -7,638 | -9,487 | -9,595 | -6,742 | -8,993 | -4,691 | -5,257 | -1,543 |
Balance Sheet | |||||||||
---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 55.5% | 154 | 99.00 | 91.00 | 103 | 110 | 120 | 121 | 65.00 |
Current Assets | 28.7% | 126 | 98.00 | 90.00 | 99.00 | 107 | 117 | 120 | 60.00 |
Cash Equivalents | -20.1% | 33.00 | 41.00 | 27.00 | 27.00 | 29.00 | 41.00 | 83.00 | 12.00 |
Liabilities | 32.9% | 15.00 | 11.00 | 9.00 | 7.00 | 4.00 | 4.00 | 5.00 | 3.00 |
Current Liabilities | 33.0% | 15.00 | 11.00 | 9.00 | 7.00 | 4.00 | 4.00 | 5.00 | 3.00 |
Shareholder's Equity | 58.3% | 139 | 88.00 | 83.00 | 95.00 | 106 | 116 | 115 | - |
Retained Earnings | -13.8% | -137 | -120 | -105 | -89.72 | -77.88 | -66.54 | -56.42 | -47.38 |
Additional Paid-In Capital | 32.5% | 277 | 209 | 188 | 185 | 184 | 183 | 172 | - |
Shares Outstanding | 35.6% | 30.00 | 22.00 | 19.00 | 19.00 | 14.00 | 11.00 | 3.00 | 3.00 |
Cashflow (Quarterly) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Cashflow From Operations | 8.0% | -11,800 | -12,824 | -11,596 | -7,638 | -9,487 | -9,595 | -6,742 | -8,993 | -4,691 | -5,257 | -1,543 |
Share Based Compensation | 11.6% | 2,169 | 1,943 | 2,068 | 1,472 | 1,228 | 1,242 | 449 | 433 | 354 | 179 | 8.00 |
Cashflow From Investing | -893.0% | -62,462 | 7,877 | 10,887 | 6,055 | -2,317 | -39,486 | 13,977 | - | - | - | - |
Cashflow From Financing | 246.8% | 66,066 | 19,050 | 199 | - | -10.00 | 7,178 | 63,187 | -969 | -240 | - | 79,744 |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Operating expenses: | ||||
Research and development | $ 14,429 | $ 7,428 | $ 39,952 | $ 19,759 |
Research and development - related party | 1,000 | 1,000 | ||
General and administrative | 3,751 | 3,342 | 10,868 | 9,027 |
Total operating expenses | 18,180 | 11,770 | 50,820 | 29,786 |
Loss from operations | (18,180) | (11,770) | (50,820) | (29,786) |
Other income, net | 1,473 | 431 | 2,986 | 672 |
Net loss | (16,707) | (11,339) | (47,834) | (29,114) |
Accretion to redemption value and cumulative dividends on preferred stock | (1,820) | |||
Net loss attributable to common stockholders | $ (16,707) | $ (11,339) | $ (47,834) | $ (30,934) |
Net loss per share attributable to common stockholders, basic | $ (0.65) | $ (0.59) | $ (2.22) | $ (2.21) |
Net loss per share attributable to common stockholders, diluted | $ (0.65) | $ (0.59) | $ (2.22) | $ (2.21) |
Weighted-average number of shares used in computing net loss per share, basic | 25,645,421 | 19,347,148 | 21,532,537 | 13,987,862 |
Weighted-average number of shares used in computing net loss per share, diluted | 25,645,421 | 19,347,148 | 21,532,537 | 13,987,862 |
Other comprehensive loss: | ||||
Unrealized gain (loss) on investments | $ (3) | $ (181) | $ 252 | $ (514) |
Comprehensive loss | $ (16,710) | $ (11,520) | $ (47,582) | $ (29,628) |
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 32,616 | $ 27,219 |
Short-term investments | 91,202 | 68,840 |
Prepaid expenses and other current assets | 2,591 | 2,509 |
Right-of-use asset, net | 53 | |
Total current assets | 126,409 | 98,621 |
Long-term investments | 26,356 | 3,219 |
Other assets, long-term | 1,043 | 720 |
Total assets | 153,808 | 102,560 |
Current liabilities: | ||
Accounts payable | 4,877 | 2,122 |
Accrued compensation | 2,196 | 2,168 |
Accrued liabilities | 6,790 | 2,837 |
Other current liabilities | 973 | |
Operating lease liabilities | 53 | |
Options subject to repurchase, short-term | 3 | 6 |
Total current liabilities | 14,839 | 7,186 |
Options subject to repurchase, long-term | 2 | |
Total liabilities | 14,839 | 7,188 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022 | ||
Common stock, $0.00001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 29,741,445 and 19,402,658 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | ||
Additional paid-in capital | 276,648 | 185,469 |
Accumulated other comprehensive loss | (122) | (374) |
Accumulated deficit | (137,557) | (89,723) |
Total stockholders' equity | 138,969 | 95,372 |
Total liabilities and stockholders' equity | $ 153,808 | $ 102,560 |